<sup>18</sup>F-氟脱氧葡萄糖显像在肺癌治疗中应用价值的

孙建鹰; 杜明华

¹⁸F-氟脱氧葡萄糖显像在肺癌治疗中应用价值的

孙建鹰¹,
杜明华²

1. 210009 南京, 东南大学临床医学院;
2. 210009 南京, 东南大学附属中大医院核医学科
基金项目:
江苏省教育厅技术创新项目(7625003030)

The new advancement of application value of imaging techniques used ¹⁸F-fluorodeoxyglucose in therapy of lung cancer

SUN Jian-yin¹,
DU Ming-hua²

1. Medical College, Southeast University, Nanjing 210009, China;
2. Department of Nuclear Medicine, Zhongda Hospital, Southeast University, Nanjing 210009, China

摘要: 肺癌的发病率很高,且其预后差,而传统的相关检查对肺癌的确诊、分期、监测疗效和探测肿瘤复发方面存在一定局限性。¹⁸F-氟脱氧葡萄糖显像作为一种功能影像已较广泛地应用于临床,由于其一次检查可获得全身图像且在辨别生理性摄取和病理性摄取上有明显优势,故对肺癌的淋巴结及全身远处器官转移均可从不同层面和角度进行观察,从而获得更准确的分期,影响肺癌治疗方案的制定及预后的判断。
- 肺肿瘤 /
- 氟脱氧葡萄糖F18 /
- 肿瘤分期 /
- 肿瘤复发,局部
Abstract: The morbidity of lung cancer is so high in china, and the prognosis of lung cancer is low.The traditional imaging techniques based on anatomic structure showing show great disadvantages in diagnosis, staging, therapy monitoring and recrudescence identification in patients with lung cancer.As a developer for cellular metabolism, imaging techniques used ¹⁸F-fluoro-deoxyglucose (¹⁸F-FDG) is increasingly being used in clinical now.It can obtain all images from one whole-body scan and it is good for identification of physiological radioactivity or pathological radioactivity.So it is a better choice for identification of lymph node and other organ metastasis, to provide important evidence for clinical staging and treatment planning of lung cancer.
- Lung neoplasms /
- FluorodeoxyglucoseF18 /
- Neoplasms staging /
- Neoplasms rengression, spontaneous
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Lee ST,Berlangieri SU,Poon AM,et al.Prevalence of occult metastatic disease in patients undergoing ¹⁸F-FDG PET for primary diagnosis or staging of lung carcinoma and solitary pulmonary nodules[J].Inter Med J,2007,37(11):753-759.
[2]	刘兰平,于金明,郭洪波,等.¹⁸F-FDGPET-CT确定非小细胞肺癌淋巴结放疗靶区的初步探讨[J].中华肿瘤杂志,2007,29(6):453-456. 0
[3]	Antoch G,Stattaus J,Nemat AT,et al.Non-small cell lung cancer:dual-modality PET/CT in preoperative staging[J].Radiology,2003,229(2):526-533.
[4]	Kim YK,Lee KS,Kim BT,et al.Mediastinal nodal staging of nonsmall cell lung cancer using integrated ¹⁸F-FDG PET/CT in a tuberculosis-endemic country:diagnostic efficacy in 674 patients[J].Cancer,2007,109(6):1068-1077.
[5]	Yi CA,Lee KS,Kim BT,et al.Efficacy of helical dynamic CT versus integrated PET/CT for detection of mediastinal nodal metastasis in non-small cell lung cancer[J].A JR Am J Roentgenol,2007,188(2):318-325.
[6]	Lee BE,yon Haag D,Lown T,et al.Advances in positron emission tomography technology have increased the need for surgical staging in non-small cell lung cancer[J].J Thorac Cardiovasc Surg,2007,133(3):746-752.
[7]	Borrego Doradol,Lopez Garcia C,Vazquez Albertion R,et al.Evaluation of efficacy and clinical impact of FDG-PET on patients with potentially respectable non-small cell lung cancer[J].Rev Esp Med Nucl,2007,26(6):335-344.
[8]	Hellwig D,Graeter TP,Ukena D,et al.ISF-FDG PET for mediastinal staging of lung cancer:which SUV threshold makes sense?[J].J Nucl Med,2007,48(11):1761-1766.
[9]	刘方颖,张雪林,商健彪,等.¹⁸F-FDG PET显像在肺癌纵隔淋巴结转移诊断中的应用[J].第一军医大学学报,2004,24(10):1186-1187.
[10]	Higashi K,Ito K,Hiramatsu Y,et al.¹⁸F-FDG uptake by primary tumor as a predictor of intratumoral lymphatic vessel invasion and lymph node involvement in non-small cell lung cancer:,analysis of a muhicenter study[J].J Nucl Med,2005,46(2):267-275.
[11]	Guhlmann A,Storck M,Kotzerke J,et al.Lymph node staging in non-small cell lung cancer,evaluation by[18F]FDG positron emission tomography (PET)[J].Thorax,1997,52(5):438-441.
[12]	Uesaka D,Demura Y,Umeda Y,et al.Evaluation of FDG-PET imaging for the detection of gastrointestinal tract cancer in patients with suspected lung cancer[J].Nihon Kokyuki Gakkai Zasshi,2006,44(12):899-905.
[13]	Cheran,S K,Hemdon JE 2nd,Patz EF Jr.Comparison of wholebody FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer[J].Lung Cancer,2004,44(3):317-325.
[14]	Ishiguro T,Fu Y,Sadatou T,et al.Detection of unknown primary tumor in a patient with cerebellar metastasis using FDG PET-CT:ease report[J].No Shinkei Geka,2006,34(10):1027-1032.
[15]	Sung YM.Lee KS.Kim BT,et al.Nonpalpable supraclavicular lymph nodes in lung cancer patients:preoperative characterization with ¹⁸F-FDG PET/CT[J].AIR Am J Roentgenol,2008,190(1):246-252.
[16]	Schaffler GJ,Wolf G,Schoellnast H,et al.Non-small cell lung cancer:evaluation of pleural abnormalities on CT scans with 18F FDG PET[J].Radiology,2004,231(3):858-865.
[17]	Yun M,Kim W,Alnafisi N,et al.¹⁸F-FDG PET in characterizing adrenal lesions detected on CT or MRI[J].J Nucl Med,2001,42(12):1795-1799.
[18]	Eschmann SM,Friede G,Paulsen F,et al.Impact of staging with 18F-FDG-PET on outcome of patients with stage Ⅲ non-small cell lung cancer:PET identifies potential survivors[J].Eur J Nucl Med Mol hnaging,2007,34(1):54-59.
[19]	Berghmans T,Dusart M,Paesmans M,et al.Primary tumor standardized uptake value (SUVmax) measnred on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC):a systematic review and meta-analysis (MA) by the european lung cancer working party for the IASLC lung cancer staging project[J].J Thorac Oncol,2008,3(1):6-12.
[20]	Goodgame B,Pillot GA,Yang Z,et al.Prognostic value of preoperative positron emission tomography in reseeted stage I nonsmall cell lung cancer[J].J Thorac Oncol,2008,3(2):130-134.
[21]	Raz DJ,Odisho AY,Franc BL,et al.Tumor fluoro-2-deoxy-Dglucose avidity on positron emission tomographie scan predicts mortality in patients with early-stage pure and mixed bronchioloal-veolar carcinoma[J].J Thorac Cardiovasc Surg,2006,132(5):1189-1195.
[22]	Eschmann SM,Friedel G,Paulsen F,et al.Repeat ¹⁸F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer[J].Lung Cancer,2007,55(2):165-171.
[23]	Eschmann SM,Friedel G,Paulsen F,et al.¹⁸F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer[J].Eur J Nucl Med Mol Imaging,2007,34(4):463-471.
[24]	刘素文,于金明,邢力刚.¹⁸F-FDG PET显像在非小细胞肺癌临床分期中的价值[J].中华肿瘤杂志,2004,26(10):626-629.
[25]	van Baardwijk A,Bosmans G,Dekker A,et al.Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy.A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients[J].Radiother Oncol,2007,82(2):145-152.
[26]	Hicks RJ,Kalff V,MacManus MP,et al.The utility of (18) F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy:impact on management and prognostic stratification[J].J Nucl Med,2001,42(11):1605-1613.
[27]	Higashi K,Ueda Y,Arisaka Y,et al.¹⁸F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer[J].J Nucl Med,2002,43(1):39-45.
[28]	向作林,吴铮,陈刚,等.¹⁸F-脱氧葡萄糖hPET显像诊断非小细胞肺癌放化疗后复发病灶的价值[J].中国癌症杂志,2005,15(2):161-163.
[29]	Brink I,Schumaeher T,Mix M,et al.Impact of[18F]FDG-PET on the primary staging of small-cell lung cancer[J].Eur J Nucl Med Mol Imaging,2004,31(12):1614-1620.
[30]	Kut V,Spies W,Spies S,et al.Staging and monitoring of small cell lung cancer using[18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET)[J].Am J Clin Oncol,2007,30(1):45-50.
[31]	Mansueto M,Grimaldi A,Torbica A,et al.Cost-effectiveness analysis in the clinical management of patients with known or suspected lung cancer:[(18F)]fluorodeoxygtucose PET and CT comparison[J].Q J Nucl Med Mol Imaging,2007,51(3):224-234.

[1]	邢岩 , 赵晋华 . ¹⁸F-氟脱氧葡萄糖PET及PET-CT早期诊断肿瘤复发. 国际放射医学核医学杂志, 2007, 31(6): 341-344.
[2]	李亚军 , 白人驹 , 高硕 , 李彦生 , 刘磊 , 贾薇 , 蔡莉 , 邢喜玲 . 兔VX2肺肿瘤PET-CT与血管生成的相关性研究. 国际放射医学核医学杂志, 2010, 34(3): 139-142. doi: 10.3760/cma.j.issn.1673-4114.2010.03.003
[3]	曹霞 , 谢爱民 , 莫逸 , 彭翔 . ¹⁸F-氟脱氧葡萄糖PET-CT在非小细胞肺癌临床分期及经治患者疗效评价中的应用. 国际放射医学核医学杂志, 2008, 32(4): 214-216.
[4]	孙琳 , 高再荣 , 张永学 . ¹⁸F-氟代脱氧葡萄糖PET-CT用于恶性肿瘤治疗疗效评估与监测. 国际放射医学核医学杂志, 2006, 30(6): 328-331.
[5]	吕慧清 , 张中民 , 吕仲虹 . ¹⁸F-氟代脱氧葡萄糖PET在恶性肿瘤适形放射治疗中的价值. 国际放射医学核医学杂志, 2006, 30(6): 335-337.
[6]	张玉娜 , 赵晋华 . ¹⁸F-氟脱氧葡萄糖PET-CT在头颈部肿瘤临床诊治中的价值. 国际放射医学核医学杂志, 2007, 31(6): 359-362.
[7]	田亚东 , 袁卫红 . 影像学及肿瘤相关抗原在诊断肺癌中的应用. 国际放射医学核医学杂志, 2011, 35(5): 295-299. doi: 10.3760/cma.j.issn.1673-4114.2011.05.011
[8]	陈艳芳 , 杨天恩 , 曹永珍 . 放射性脑损伤和脑肿瘤复发的鉴别诊断. 国际放射医学核医学杂志, 2006, 30(5): 308-311.
[9]	叶慧 , 莫逸 , 谢爱民 , 彭翔 . ¹⁸F-氟脱氧葡萄糖PET-CT与99nTc-亚甲基二膦酸盐骨显像诊断转移性骨肿瘤的对比研究. 国际放射医学核医学杂志, 2008, 32(3): 147-150.
[10]	董晖 , 王朝杰 . 结直肠癌患者免疫状况与肿瘤分期的关系. 国际放射医学核医学杂志, 2005, 29(3): 115-117.

点击查看大图

计量

文章访问数: 1437
HTML全文浏览量: 94
PDF下载量: 2

¹⁸F-氟脱氧葡萄糖显像在肺癌治疗中应用价值的

The new advancement of application value of imaging techniques used ¹⁸F-fluorodeoxyglucose in therapy of lung cancer

计量

¹⁸F-氟脱氧葡萄糖显像在肺癌治疗中应用价值的

English Abstract

The new advancement of application value of imaging techniques used ¹⁸F-fluorodeoxyglucose in therapy of lung cancer

全文HTML

目录

18F-氟脱氧葡萄糖显像在肺癌治疗中应用价值的

The new advancement of application value of imaging techniques used 18F-fluorodeoxyglucose in therapy of lung cancer

计量

出版历程

18F-氟脱氧葡萄糖显像在肺癌治疗中应用价值的

English Abstract

The new advancement of application value of imaging techniques used 18F-fluorodeoxyglucose in therapy of lung cancer

全文HTML

目录

¹⁸F-氟脱氧葡萄糖显像在肺癌治疗中应用价值的

The new advancement of application value of imaging techniques used ¹⁸F-fluorodeoxyglucose in therapy of lung cancer

¹⁸F-氟脱氧葡萄糖显像在肺癌治疗中应用价值的

The new advancement of application value of imaging techniques used ¹⁸F-fluorodeoxyglucose in therapy of lung cancer